Tag:

Merck

Latest Headlines

Latest Headlines

Merck aims to boost HPV vaccination rates amid lagging numbers

Though Merck's Gardasil tops the company's best-selling vaccines list and has already achieved blockbuster sales, the drug giant has a long way to go if it wants to boost U.S. immunization rates against human papillomavirus.

Resurgent Merck to accelerate R&D spending in H2, hunt new drug deals

With investors focused almost exclusively on earnings and R&D programs today, Merck quietly managed to slip in news of a setback in its quarterly report, noting that the FDA has rejected its marketing application for the fertility treatment corifollitropin alfa.

Merck beats Q2 earnings estimates, but mostly on cost-cutting

Merck surprised Wall Street analysts today when it announced that its net profit in the second quarter jumped to $2 billion from $906 million in the same period a year ago, and that it was raising the lower end of its income forecast for 2014. But it's not exactly time to pop out the champagne corks and declare a successful turnaround.

Merck spokeswoman: Sales layoffs to hit PA-based field reps

The job-cutting ax has come out for Merck's U.S. field force, as part of a move to cut 600 positions by August. 

Merck spokeswoman: Sales layoffs to hit PA-based field reps

Merck's patent cliff has the company struggling to cut costs while it scrambles to make up for lost revenue, and sales and marketing has been no exception. Now, the job-cutting ax has come out for Merck's U.S. field force, where 600 positions will be chopped by August. Most at risk: Pennsylvania-based sales folks focused on declining primary care meds.

Top 10 animal health companies of 2013

It is fascinating what has happened in the last couple of years in the animal health industry, which runs to $22 billion a year for animal drugs and vaccines and is expected to grow at 5.7% compound...

USDA, Nebraska U. researchers find no danger in Merck's Zilmax

A study carried out the University of Nebraska, Lincoln and the U.S.D.AU Agricultural Research Service found Zilmax had no negative effects on cattle health.

Merck whacks 600 sales reps as part of 8,500 bloodletting

Merck is going through a complete makeover, buying and selling units at a rapid pace. And some of its employees are getting caught in its "out with the old and in with the new" philosophy. Now 600 sales reps have been told their services are no longer needed

The top 5 vaccine makers by 2013 revenue

Vaccines, which can be complicated and expensive to manufacture, haven't always been the moneymakers they are for some drugmakers today. Last year, the global vaccines market topped $25.56 billion according to Evaluate Pharma, with the world's 6 top-selling shots each cracking the blockbuster barrier.

Gilead litigation says claims by Merck, AbbVie on Sovaldi are patently wrong

Gilead Sciences got to the market first with an interferon-free oral hepatitis C fighter, a category projected to hit $20 billion in sales by 2020. Its Sovaldi has been racking up unprecedented sales, and a raft of litigation, as other drugmakers look for a way to get a piece of that action.